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12Abstract Leukemic cells are hard-to-transfect cell lines. Many transfection reagents
13which can provide high gene transfer efficiency in common adherent cell lines are not
14effective to transfect established blood cell lines or primary leukemic cells. This study
15aims to examine a new class of cationic polymer non-viral vector, PEGylated–
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16dextranu–spermine (PEG-D-SPM), to determine its ability to transfect the leukemic
17cells. Here, the optimal conditions of the complex preparation (PEG-D-SPM/plasmid
18DNA (pDNA)) were examined. Different weight-mixing (w/w) ratios of PEG-D-
19SPM/pDNA complex were prepared to obtain an ideal mixing ratio to protect encap-
20sulated pDNA from DNase degradation and to determine the optimal transfection
21efficiency of the complex. Strong complexation between polymer and pDNA in
22agarose gel electrophoresis and protection of pDNA from DNase were detected at
23ratios from 25 to 15. Highest gene expression was detected at w/w ratio of 18 in
24HL60 and K562 cells. However, gene expression from both leukemic cell lines was
25lower than the control MCF-7 cells. The cytotoxicity of PEG-D-SPM/pDNA complex
26at the most optimal mixing ratios was tested in HL60 and K562 cells using MTS
27assay and the results showed that the PEG-D-SPM/pDNA complex had no cytotoxic
28effect on these cell lines. Spherical shape and nano-nature of PEG-D-SPM/pDNA
29complex at ratio 18 was observed using transmission electron microscopy. As PEG-D-
30SPM showed modest transfection efficiency in the leukemic cell lines, we conclude
31that further work is needed to improve the delivery efficiency of the PEG-D-SPM.
32Keywords Non-viral . Gene delivery . Dextran–spermine . Nanoparticles . Cationic polymer
33
34Introduction
35Hematological malignancies are of interest for gene transfer approaches due to several
36factors such as: (1) The neoplastic cells circulate in the blood, thus large numbers of tumor
37cells can be harvested and sorted for ex vivo manipulation, and (2) the efficiency of gene
38transfer and transgene effects can be monitored from direct analysis of the blood. Gene
39transfer approaches in malignant blood cells needs an appropriate vector to achieve high
40gene transfer efficiency, without major cytotoxicity. Many transfection reagents which show
41high gene transfer efficiency in common adherent cell lines are not effective to transfect
42established blood cell lines or primary leukemia cells from patients [1].
43An essential factor for a successful gene therapy for hematological disease is the
44development of a vehicle that can selectively and efficiently deliver gene to target cells.
45Early efforts in vector design have focused primarily on genetically engineered viruses [2–
464]. Nevertheless, intrinsic limitations related to the viral vectors, such as safety concerns,
47have limited their use in the clinic [5]. Non-viral synthetic vectors are, consequently, being
48designed as the substitutes to the viral vectors [6]. Non-viral vectors are easy to produce
49since they are chemically based materials and freely designed. In addition, they exhibit low
50toxicity with minimal possibility of genetic integration into the host’s genome [7, 8].
51Unfortunately, the non-viral vectors show lower efficacy of gene transfer compared with
52the viral systems [9, 10]. Two classes of the synthetic gene delivery systems being mostly
53investigated are cationic lipids and cationic polymers [11].
54Polycationic vectors neutralize the negative charge of DNA and decrease the electrostatic
55repulsion between DNA and cells. They also protect DNA from enzymatic digestion by
56nucleases in serum and extracellular fluids [12]. Polycations commonly used in gene
57delivery are polyethylenimine (PEI) [13], poly(L-lysine) [14], poly-brene [15], gelatin [16],
58and cationic polysaccharides [17]. Most polycations are toxic to cells and nonbiodegradable.
59The high cationic charge of polycations mediates DNA condensing and buffering capacities,
60therefore, the requirement for the addition of endosomolytic agents will decrease [18, 19]. The
61activity of polycation is related to their molecular weight, polymer type, polymer–DNAmixing
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62ratio, and molecular structure. We have previously reported on the use of polycation in
63combination with principal of tissue engineering to enhance in vitro gene transfection [20–24].
64Cationic polysaccharides are known to be one of the most attractive candidates
65among the various polycations for transfection. They are natural, non-toxic, biode-
66gradable, and biocompatible materials and can be easily modified for improved
67physicochemical properties [25, 26]. Our research team has constructed a new type
68of biodegradable polycation, dextran–spermine (D-SPM), based on grafted oligoamine
69residues on natural polysaccharides. They are effective in delivering plasmids for a
70high biological effect. As these carriers are water-soluble, they can be readily
71transported to cells by known biological processes and perform as effective vehicles
72for transporting agents complexed to them [27]. D-SPM polycations are prepared by
73the reductive amination synthesis between oxidized dextran (dialdehyde derivatives)
74and the naturally occurring tetramine spermine [28]. The spermine residues in D-SPM
75polycations play a crucial role in cell transfection. Therefore, D-SPM conjugates are
76active in transfecting a wide range of cell lines [28–30].
77Conjugation of polycation with polyethylene glycol (PEG) reduces particle aggregation
78in buffers, specifically in the aqueous medium and maintains them aggregation-free after
79lyophilization. PEG modification of the polycation can increase circulation time and signif-
80icantly reduces plasma protein adsorption in vivo [31]. It was reported that D-SPM conju-
81gated with PEG showed high level of gene expression in the liver after intravenous injection
82when compared with D-SPM, which showed no expression in all organs. Generally,
83PEGylation of D-SPM showed remarkable increase in the complex stability and transfection
84efficiency in serum-rich media [9, 28].
85To date, no study has been performed to determine the transfection efficiency of
86PEGylated-D-SPM polycation in leukemic cells. Here, we determined the optimal condi-
87tions for gene expression in leukemic cell lines via the transfection of PEG-D-SPM/plasmid
88DNA (pDNA) complexes. The complexation and stability of PEG-D-SPM was also inves-
89tigated. In vitro cytotoxicity of the polymer was evaluated, and transfection efficiency of
90PEG-D-SPM/pDNA complexes in suspension leukemic cells and adherent cells was com-
91pared. The application of PEG-D-SPM in this study is to improve and maintain the
92physicochemical stability of D-SPM in transfection media and especially in the blood stream
93for subsequent in vivo study.
94Materials and Methods
95Preparation of Plasmid DNA
96Plasmid pcDNA3.1+ carrying green fluorescent protein (GFP) reporter gene was prepared by
97isolation of hMGFP gene in the HindIII–NotI restriction sites of phMGFP plasmid
98(Promega, Madison, WI, USA) and insertion in the same restriction sites of pcDNA3.1+
99(Invitrogen, Carlsbad, CA, U.S.A). The constructed plasmid is under the control of CMV
100promoter and enhancer. The length of the expected product was 1,023 bp and was confirmed
101by gel electrophoresis analysis. Following digestion, ligation, and transformation of JM109
102cells (Invitrogen Co., USA), positive colonies were selected and confirmed by endonuclease
103digestion. Positive colonies were then sequenced for final verification. Finally,
104pCDNA3.1/hMGFP plasmid was purified using the EndoFree Plasmid Mega Kit (Qiagen,
105Valencia, CA). The purity and concentration of constructed plasmid was determined using
106Nanodrop (Thermo, Wilmington, DE, USA).
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107Preparation of PEG-D-SPM/pDNA Complex
108Complexation of PEG-D-SPM with the pDNA was performed by mixing the two materials
109at various weight-mixing (w/w) ratios. Briefly, 150 μl 0.1 M deionized phosphate-buffered
110saline solution (DPBS, pH 7.4) containing 100, 90, 80, 70, 60, 50, 40, and 30 μg of PEG-D-
111SPM was added to the same volume of PBS containing 4 μg of pDNA, respectively. The
112final solution was gently agitated at room temperature (RT) for 30 min to form PEG-D-
113SPM/pDNA complexes.
114Gel Retardation Assay
115To identify DNA condensation ability of the PEG-D-SPM, agarose gel electrophoresis was
116performed. The cationic PEG-D-SPM/pDNA complexes with different weight-mixing ratios
117(25, 22.5, 20, 17.5, 15, 12.5, 10, and 7.5) in DPBS buffer were prepared and incubated for
11830 min at RT. Next, 10 μL of complex suspension containing 4 μg of DNA was
119electrophoresed on the 0.75 % (w/v) agarose gel in 1× of Tris–acetate–EDTA (TAE) running
120buffer at 80 V for 40 min. Then, the gel was stained and visualized under Alpha-Innotech gel
121documentation system (San Leandro, CA).
122Complex Sensitivity to DNAse I Digestion
123DNase I protection assay was performed on several weight-mixing ratios of PEG-D-
124SPM/pDNA complexes as in the gel retardation assay. Briefly, 8 μl of each complex was
125incubated with 2 units of DNase I (Promega, USA) at 37 °C for 30 min in a final volume of
12610 μL. The reaction was inactivated by the addition of stop solution following incubation at
12765 °C for 10 min. The integrity of pDNA released from the complexes was assessed by
128agarose gel electrophoresis as described above.
129Cell Culture
130In vitro assays were performed on K562 (human erythromyeloblastoid leukemia cell line)
131and HL60 (human promyelocytic leukemia cell line) purchased from American Type Culture
132Collection (ATCC, Manassas, VA, USA). The cells were cultured in RPMI with 10 % fetal
133bovine serum (FBS) (Hyclone, Austria). MCF-7 cells (human breast adenocarcinoma cell
134line) (ATCC, USA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
135supplemented with 10 % FBS and were used as the control. The cells were incubated at
13637 °C in humidified 5 % CO2.
137Cytotoxicity Assay
138The CellTiter 96® AQueous non-radioactive cell proliferation assay (MTS) was used to
139evaluate the effects of PEG-D-SPM/pDNA on HL60 and K562 cells viability by measuring
140the uptake and reduction of MTS compound into a colored formazan product that is soluble
141in tissue culture medium. The quantity of formazan product as measured by the amount of
142490 nm absorbance is directly proportional to the number of living cells in culture using
143ELISA microplate reader (Tecan, Austria). Different weight-mixing ratios of PEG-D-
144SPM/pDNA were prepared [10, 12, 14, 16, 18, 20, 22, 24], with a fixed concentration of
145pDNA (0.5 μg) scaling up to a total of 200 μl OptiMEM® I medium (Invitrogen Co., USA).
146The samples were mixed for 5 min and incubated at room temperature for 30 min. Then,
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147100 μl of each ratio was added in the 96-well plates containing 1×104 cells/well. The plates
148were incubated in 37 °C in humidified 5 % CO2 atmosphere for 72 h. The cell viability was
149calculated by the following formula: cell viability (%)=optical density (OD) of the treated
150cells/OD of the non-treated cells.
151Transfection of Cells Grown In Vitro
152MCF-7 cells were seeded at an initial density of 1×105 cells/well on a 24-well plate and
153grown in 500 μl DMEM and 10 % FBS. HL60 and K562 cells were seeded at density of 5×
154105 cells/well in 500 μl RPMI and 10 % FBS on a 24-well plate and incubated in 37 °C for
15524 h prior to transfection. The PEG-D-SPM/pDNA complexes were formed at different
156weight-mixing ratios (10, 12, 14, 16, 18, and 20 w/w). However, each formulation of
157complexes contained 0.5 μg of pcDNA3.1 according to the conditions describe above. At
158time of transfection, cell growth medium was aspirated and replaced with 200 μl of the
159transfection mixture. At 4 h post-transfection, 500 μl complete growth medium was added to
160each well, and cells were incubated for 72 h. Branched 25 kDa PEI (Sigma-Aldrich Co.,
161USA) and lipofectamine 2000 (Invitrogen Co., USA) were used as the positive controls.
162Briefly, PEI/pDNA (10: 1 N/P ratio) in a total of 420 μL Opti-MEM®I was added to each
163well and incubated for 24 h. Then, the transfection media were exchanged with complete
164growth media and further incubated for another 48 h. The lipofectamine 2000/pDNA
165(2 μl/0.5 μg) complex in a total of 100 μl OptiMEM®I was added to each well and
166incubated for 4 h at 37 °C in a CO2 incubator. The transfection media was replaced with
167fresh complete media, followed by incubation at 37 °C for another 72 h.
168Reporter Gene Expression Analysis
169To determine the transfection efficiency, cells were harvested and washed with 1×
170DPBS and then resuspended in 1× DPBS/2%FBS in a FACS tube (BD Biosciences,
171San Jose, USA). An aliquot of suspension were analyzed for GFP expression using
172flow cytometry (BD Biosciences, USA). Side and forward scatter signals were applied
173to limit the analysis to viable cells. The data were analyzed with the aid of CellQuest
174Software (Becton Dickinson). The K562 and MCF-7 cells transfected with the same
175condition mentioned above were also used for observation of GFP expression under
176inverted fluorescent microscope (Olympus 1X 51, Olympus Corporation, Japan).
177Transmission Electron Microscope (TEM)
178The PEGylated-D-SPM/pDNA complexes were prepared to a fixed weight-mixing ratio of
17918 in nuclease-free water. The aqueous solution was transferred to the transmission electron
180microscopy (TEM)-gold grids to determine the shape and average diameter of the particles.
181TEM was performed by the Microscopy Unit, Institute of Bioscience, Universiti Putra
182Malaysia.
183Statistical Analysis
184All analyses were performed using SPSS 16.0 software. Before analysis, all data were
185subjected to Kolmogorov–Smirnov test for normality. To show the differences among
186groups, ANOVA was applied. Mean comparison was done using Duncan multiple range
187test. The comparison of results between or among the groups was analyzed by paired sample
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188t test. Test results were considered statistically significant if the probability was less than
1890.05.
190Results
191Physiochemical Properties of the PEG-D-SPM/pDNA
192Determination of Optimal Weight-Mixing Ratio of PEG-D-SPM/pDNA
193The strength of complexation of PEG-D-SPM with pDNA was determined by performing
194gel retardation assay (0.75 % agarose gel). The weight-mixing ratio was calculated consid-
195ering that a fixed amount of pDNA (micrograms) corresponds to different concentration
196(micrograms) of PEG-D-SPM. From Fig. 1, it was observed that the electrostatic interaction
197between the polymer and pDNA completely hampered the free movement of the pDNA at
198ratios 25–15 (lanes 1–5). The higher intensity of fluorescence was observed at lanes 1–4, and
199it gradually diffused as the weight ratio decreased. As the polymer concentration decreased
200(ratios 12.5 to 7.5), the PEG-D-SPM gradually lost its ability to hamper pDNA mobility
201(lanes 6–8).
202Stability of PEG-D-SPM Complex in Presence of DNase
203Different weight-mixing ratio of PEG-D-SPM/pDNA complexes (as described above)
204and free pDNA were treated with DNase I and subsequently incubated for 30 min at
20537 °C. After incubation, stop solution was added to each mixture to end the reaction.
206The protection assay was determined by the detection of the intensity of fluorescence
207from the DNA bands. Figure 2 shows the DNase I challenge study on agarose gel.
208The intense fluorescence was seen in some loading wells (lanes 1–5) whereas diffused
209fluorescence was detected in other wells (lanes 6–8). The PEG-D-SPM/pDNA at ratios
21017.5 and 15 presented maximum protection as the higher intensity of fluorescence was
211observed in the well (lanes 4 and 5). The uncomplexed pDNA was rapidly degraded
212by DNase I (lane 9).
Fig. 1 Agarose gel electrophoresis of PEG-D-SPM/pDNA complexes at different weight ratios. Lane M, 1 kb
DNA ladder; lanes 1–8, PEG-D-SPM/pDNA complexes at ratios 25, 22.5, 20, 17.5, 15, 12.5, 10, 7.5; lane 9,
free pDNA
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213In Vitro Cytotoxicity
214In cytotoxicity assay, the different concentrations of PEG-D-SPM ranging from 10 to 24 μg
215were added to a fixed amount of plasmid DNA (0.5 μg). The readings from PEG-D-
216SPM/pDNA complexes along with PEI/pDNA and lipofectamine/pDNA were taken in
217triplicates. The treated cells were normalized against the untreated cells. The percent
218viability of cells was compared in Fig. 3. The quantitative evaluation of cytotoxicity by
219the MTS assay of cells after contact with the complexes showed more than 90 % metabol-
220ically active cells for each gene carrier. No significant difference between the viability of
221K562 and HL60 cells by all three gene carriers was observed.
222In Vitro Transfection Activity
223The transfection efficiency of PEG-D-SPM/pDNA (carrying hMGFP reporter gene) was
224assessed in MCF-7, HL60, and K562 cells at different weight-mixing ratios (w/w) from 10–
22520. After 72 h, GFP expression was evaluated using flow cytometry in transfected cells to
M 1 2 3 4 5 6 7 8 9
Fig. 2 Agarose gel electrophoresis of PEG-D-SPM/pDNA complexes following DNase I digestion. Lane M,
1 kb DNA ladder; lanes 1–8, DNase I-treated PEG-D-SPM/pDNA complexes at weight ratios 25, 22.5, 20,
17.5, 15, 12.5, 10, 7.5; lane 9, DNase I-treated naked DNA
Fig. 3Q3 Cytotoxicity effect of PEG-D-SPM/pDNA complexes at different weight ratios, PEI, and
lipofectamine 2000. The cell viability was evaluated by the MTS assay. The values represent the percentage
of viable cells following 72 h of treatment compared with untreated cells. Each data point is presented as mean±
SEM (p<0.05)
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226determine the ideal weight-mixing ratio that would generate the optimal gene expres-
227sion. The delivery of PEG-D-SPM/pDNA was compared with those of the commercial
228transfection reagents, PEI (cationic polycation) and lipofectamine 2000 (cationic
229liposome), in terms of delivery efficiency of each reagent in suspension (K562 and
230HL60) and adherent (MCF-7) cells. As shown in Fig. 4, among various ratios of
231PEG-D-SPM/pDNA, the highest level of GFP expression was detected at ratio 18 in
232the three cell lines. On the other hand, comparing three cell lines, MCF-7 revealed
233significantly higher GFP level at this ratio. The results of the gene delivery using PEI
234showed a low level of GFP expression in all cell lines, whereas lipofectamine
235exhibited a significantly high GFP expression in the transfected cells compared with
236the rest, especially in MCF-7 cells. In addition, by visualizing the transfected K562
237and MCF-7 cells under inverted fluorescent microscope, similar trend of GFP expres-
238sion was observed in all cells transfected by the three gene carriers (Fig. 5). As
239shown by the figure, higher level of GFP expression in K562 and MCF-7 cells was
240observed by lipofectamine compared with PEG-D-SPM and PEI. Also, higher inten-
241sity of the green fluorescence was observed in MCF-7 cells compared with K562 cells
242using lipofectamine.
243Morphological Characterization of Nanoparticles
244TEM analysis was performed when the aqueous solution of PEG-D-SPM/pDNA at ratio of
24518 was prepared and transferred to the TEM-gold grids. The representative TEM image of
246PEG-D-SPM/pDNA is shown in Fig. 6. The findings revealed the nano-nature of the
247particles and inferred that the particles are mostly spherical in shape. Analyzed particles
248covered a narrow diameter of size range between 35 and 61 nm when complexes are formed
249with pDNA. The TEM image also showed that the nanoparticle complexes are uniform in
250shape.
Fig. 4 Transfection efficiency of PEG-D-SPM/pDNA complexes at various weight ratios. PEI and
lipofectamine 2000 were used as the positive controls. GFP expression was measured 72 h post-transfection.
The fluorescence intensity of GFP-positive cells was detected using flow cytometry. The GFP expression in
treated cells was normalized against untreated cells. Each data point is presented as mean±SEM (n=3). The
significance level of GFP expression among the ratios in each group was determined according to Duncan’s
multiple test (p<0.05)
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251Discussion
252One of the most important factors for achieving an optimal transfection efficiency of
253polycation-based nanoparticles is the weight-mixing (w/w) ratio of polycation to pDNA
254[28]. The formation of strong complexation between polymer and pDNA limits the mobility
255of the DNA due to the electrostatic interaction between the pDNA and polymer [32]. In this
256study, the complexation ability of PEG-D-SPM was investigated at different w/w ratios of
257polymer/pDNA complexes using agarose gel electrophoresis. As the w/w ratio of PEG-D-
258SPM/pDNA decreased, the pDNA gradually started to move toward the anode due to the
259decrease in the shielding effect of PEG-D-SPM over pDNA. Hosseinkhani et al. reported
260that the migration of pDNA in different N/P molar ratio of D-SPM/pDNA [1–7] was
Lipo/pDNA                     PEG-D-SPM/pDNA                       PEI/pDNA
K562
MCF-7
Fig. 5 Fluorescence microscopy of K562 and MCF-7 cells transfected with gene carriers. Fluorescent cells
were visualized at 72 h post-transfection. Lipofectamine/pDNA, PEG-DSPM/pDNA (ratio 18), and PEI/
pDNA (×100 total magnification)
35.19
48.54
42.69
61.31
50.45
Fig. 6 Transmission electron microscopy (TEM) images of PEG-D-SPM/pDNA complex. PEG-D-SPM/
pDNA (ratio 18) with diameters of 35 to 61 nm, are highlighted by arrows (magnification of ×30,000)
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261retarded by increasing the N/P molar ratio (N/P=3–7) [9]. In the study by Syahril et al. gel
262retardation assays demonstrated the DNA immobility of D-SPM/pDNA complexes at ratios
263of 14, 16, and 18 [33]. In our study, the electrophoretic movement of DNA toward the anode
264was observed at weight ratio of less than 15. To explain, the ideal weight-mixing (w/w) ratio
265of polycation to pDNA is different from polymer to polymer [28]. It was also reported that
266the percentage of PEG introduced to dextran–spermine can alter the electrophoresis migra-
267tion pattern of plasmid DNA [9]. Degradation of DNA by nucleases is another factor that can
268impede the success of gene delivery [34]. In this study, the fragmentation of unprotected
269pDNA by endonuclease activity of DNase I was analyzed to evaluate the encapsulation
270strength of pDNA by PEG-D-SPM. Protection of pDNA from nuclease digestion by PEG-D-
271SPM was determined by the observation of the fluorescence in the well compared with the
272naked DNAwhere no band was seen. The identification of intense fluorescence at ratio 15 to
27325, confirmed the strong association between PEG-D-SPM and pDNA. It also showed the
274entrapment of the DNA surrounded by the polymer nanoparticles, while diffused fluores-
275cence at ratio 7.5 to 12.5 was due to the degradation of some amounts of DNA from the
276complex. In another study, the partial protection of pDNA by D-SPM was observed at ratio
27714, 16, and 18 [33]. The higher protection of pDNA from DNase activity by PEG-D-SPM
278compared with D-SPM can be due to the effect of PEG introduction in D-SPM. It was
279reported that PEG can protect the pDNA complex from interaction with enzymatic degra-
280dation and biological substances [9].
281Toxicity is still one of the barriers to the use of non-viral vectors in gene delivery [35]. In
282the current study, in vitro cytotoxicity analysis of PEG-D-SPM/pDNA complexes was
283performed at several w/w ratios ranging from 24 to 10. The PEG-D-SPM /pDNA complexes
284were found to be safe for both HL60 and K562 cells. Besides, two commercial reagents
285which were used in our study as the control for transfection efficiency showed no toxicity on
286two leukemic cell lines, as the viability of cells was more than 90 % in the MTS assay. Our
287finding is consistent with that of Hosseinkhani et al. who reported that cationized dextran,
288with or without PEG introduction, had no cytotoxic effect on mouse fibroblast L929 cells
289[9]. In addition, by using MTT assay, Kim et al. demonstrated that the D-SPM/pDNA was
290not toxic on HepG2 and HeLa cell lines [36]. Therefore, as with other studies, here we
291showed that the PEG-D-SPM/pDNA complex was safe to be used on the K562 and HL60
292cells.
293Following previous findings using gel retardation and DNA stability assays, identifica-
294tion of the optimal weight ratio of PEG-D-SPM/pDNAwas continued by performing in vitro
295transfection assay. The transfection was performed using PEG-D-SPM/pDNA (carrying
296GFP reporter gene) at ratio 10 to 20 on HL-60, K562, and MCF-7 cell lines. Flow cytometry
297analysis revealed the highest expression of GFP at ratio 18 in HL-60, K562, and MCF-7
298cells (9.88 %, 10.84 %, and 15.18 %, respectively). This can be caused by the robust
299complexation of PEG-D-SPM with DNA at ratio 18. The ratio of polymer/DNA complex is
300critical factor for transfection efficiency. The polymer/DNA ratio represents the charge ratio
301between the positively charged polymer and the negatively charged DNA resulting in strong
302complexation of polymer/DNA. Therefore, the optimal ratio of polymer/DNA affects a
303number of critical transfection properties, such as the stability, cytotoxicity, and cellular
304uptake level of the complex [37, 38].
305From this quantitative analysis, we found that the GFP expression in all three cell lines
306was proportional to the increasing w/w ratios of PEG-D-SPM/pDNA, with a significant
307decrease at ratio 20. This reduction could be due to the loss of the protecting effect of
308polymer over DNA once the complexation reaches its maximum packaging ability [39]. This
309pattern of expression was similar in all the three tested cell lines. However, there was a
Appl Biochem Biotechnol
JrnlID 12010_ArtID 224_Proof# 1 - 15/04/2013
AUTHOR'S PROOF
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
310significant difference in GFP expression in MCF-7 cells, where a higher GFP intensity was
311detected in all ratios, compared with the two other cell lines, HL60 and K562.
312In this study, PEI, a commercially available cationic polyamine, was applied as a
313control to compare its transfection efficiency in all three cell lines. Surprisingly, the
314GFP expression levels in all three cell lines transfected using the PEI/pDNA complex
315were significantly lower than the levels expressed by cells treated with PEG-D-SPM
316at the ratio of 18. As transfection activity with PEI provided low levels of GFP
317expression, especially in adherent cells (MCF-7), therefore in addition to PEI, we used
318a cationic lipid (lipofectamine 2000) with an effective delivery profile to check the
319delivery conditions in our experiments. Results of transfection with lipofectamine
3202000 showed considerable level of GFP expression compared with PEI and PEG-D-
321SPM (65.8 %, 26.18 %, and 20.85 for MCF-7, K562, and HL60, respectively).
322Besides, the fluorescence microscopy observation supported the flow cytometry re-
323sults. The transfection efficiency of D-SPM in COS-7 cells was evaluated by Syahril
324et al. where it was reported that the highest GFP expression was at ratio of 12 with
325level of expression approximately similar to our results, especially that of the MCF-7
326cells. Previous studies of D-SPM, with or without PEG modification, reported a high
327and effective transfection activity with about 50 % reporter gene expression in some
328adherent cells [10, 28]. The lower level of GFP expression in the leukemic suspension
329cells, K562 and HL60 cells, is supported by some studies which emphasized that
330leukemic cells are hard-to-transfect [40]. It was claimed that low transfection efficien-
331cy by non-viral vectors is a considerable issue in gene-transferring approaches in the
332treatment of hematologic malignancies. Also, it was reported that non-viral carriers
333usually fail in the efficient transfection of primary cells [41]. Several non-viral
334methods have been tested in human primary hematopoietic CD-34+ cells, including
335liposome-mediated transfection, particle-mediated gene transfer by gene gun, and
336electrotransfection. All studies showed low transfection efficiencies for these types
337of cells [42–44].
338The physiochemical characteristics of nanoparticle complex, including particle size,
339shape, and morphology, are very important factors affecting delivery efficiency [45, 46].
340Complex size can affect the mechanism of internalization. Trafficking of molecules between
341the cytoplasm and nucleus is size-dependent and occurs through passive diffusion or as a
342controlled process. Molecules larger than approximately 40–60 kDa need a nuclear locali-
343zation signal to actively be transported through nuclear pores with 9–10 nm diameter [47].
344Transmission electron microscopy evaluation of PEG-D-SPM/pDNA at ratio of 18, which
345showed the highest level of GFP expression, illustrated the nano-nature of the particles (less
346than 100 nm) with narrow size range of 35–61 nm. Also, the particles showed a uniform
347spherical shape which has high probability of entering the cell [48]. The observed particle
348size and shape of complex seem to be favorable for transfection as the complexation of DNA
349into small particle improves cell entry [49].
350Conclusion
351Further optimizations to discover the most optimal conditions of PEG-D-SPM for high level
352gene expression in leukemic cells is needed. Modifications on the physiochemical properties
353of the PEG-D-SPM, such as increasing the polymer length or masking the anionic charges of
354the complex, should be done before the GFP gene can be substituted with the gene of interest
355to target leukemic cells.
356
357
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